Clinical trials have confirmed the effectiveness of Daunorubicin in treating acute myeloid leukemia with the DNMT3A (p.V687F) mutation, and professional guidelines have endorsed its use [53]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.